Today: 7 February 2026
Subscribe
Browse Category

Biotech Stocks News 22 December 2025 - 30 December 2025

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

NEW YORK, December 30, 2025, 14:58 ET — Regular session Caris Life Sciences shares were down about 1.8% at $27.44 as of 2:41 p.m. ET, after trading between $27.00 and $27.97 during Tuesday’s session. The drop came as biotech stocks underperformed, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.2%. The S&P 500 was little changed and the Nasdaq was flat, Reuters data showed. Reuters That matters for Caris because the newly public cancer diagnostics company tends to move with shifts in risk appetite for healthcare growth names, even when there
30 December 2025
···
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

NEW YORK, December 30, 2025, 13:38 ET — Regular session Shares of Mineralys Therapeutics Inc fell 3.3% to $35.61 by early afternoon on Tuesday, after touching a session low of $35.17. About 513,000 shares had changed hands, versus a previous close of $36.83. Mineralys has a market value of about $2.9 billion and remains up about 183% over the past 52 weeks, even after sliding about 25% from its 52-week high set in November. Analysts expect the company to stay loss-making in the near term; Barchart shows an average quarterly EPS estimate of -$0.57 and an expected next earnings date
30 December 2025
·····
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

NEW YORK, December 30, 2025, 09:17 ET — Premarket Zenas BioPharma, Inc. shares were flat in premarket trading on Tuesday, with the stock last indicated at $39.05 as of 9:00 a.m. ET. The biotech closed down 8.1% on Monday. Public+1 The pause comes at a sensitive point on the calendar for investors: the company has told investors to expect a late-2025 update from a pivotal trial, a headline that can reset valuations quickly in clinical-stage biotech. In a Nov. 12 press release, founder and Chief Executive Officer Lonnie Moulder said the company expected to deliver “topline results” — the first
30 December 2025
···
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s market as subdued, with institutions largely “checked out” for year‑end and the broader tape moving only slightly. Reuters As of the latest available quote in this session, VERA is at about $54.24, down ~2.6% on the day, with a day range roughly $54.05–$55.30 and notably light volume—exactly the kind of trading environment where single‑stock moves can look louder than the
26 December 2025
···
Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation (NASDAQ: OMER) is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.” The spark was the U.S. FDA approval of YARTEMLEA® (narsoplimab-wuug) as the first and only therapy indicated for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA‑TMA)—a dangerous complication that can follow stem cell transplantation. Omeros says it is finalizing preparations for a U.S. launch in January 2026, with reimbursement infrastructure already in motion. Omeros Corporation With the FDA decision now public, OMER stock pushed
25 December 2025
·····
Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies Corporation (NASDAQ: DVAX) is the standout mover heading into the Christmas break after Sanofi agreed to acquire the vaccine maker in an all-cash deal valued at about $2.2 billion. The transaction price — $15.50 per share in cash — instantly re-framed DVAX from a “biotech fundamentals” story into a deal-arbitrage stock, with trading now anchored around the buyout price. Reuters+2PR Newswire+2 A timing note that matters for anyone planning “tomorrow” trades: U.S. equities had a holiday early close today (Dec. 24) at 1:00 p.m. ET, and the market is closed Thursday, Dec. 25 for Christmas. The next regular
24 December 2025
······
Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Regencell Bioscience Holdings (NASDAQ: RGC) Stock News Today: Price Action, DOJ Probe Overhang, and the Latest Forecasts on Dec. 24, 2025

Dec. 24, 2025 — Regencell Bioscience Holdings Limited (Nasdaq: RGC) is once again reminding markets that “biotech stock” plus “low float” can equal “physics optional.” By the close of trading on December 24, RGC finished at $24.60, down 2.57% from the prior close of $25.25, after trading between $24.60 and $26.42 on the day, with roughly 348K shares traded. StockAnalysis+1 That’s the headline tape. The deeper story—what’s making RGC such a recurring character in 2025’s “stock market does weird things” anthology—mixes extreme volatility, concentrated insider ownership, a past 38-for-1 stock split, and a disclosed U.S. Department of Justice (DOJ) inquiry
24 December 2025
·····
Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

Regencell Bioscience (RGC) Stock Today: Price Surge Extends December Rally as DOJ Probe and “Going Concern” Risks Loom

December 23, 2025 — Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back in the spotlight on Tuesday after another sharp move higher, extending a volatile December run that’s pulled in momentum traders—and raised fresh questions about fundamentals, governance, and legal risk. As of late morning in U.S. trading, RGC was changing hands around the mid‑$23 range after opening higher, with the day’s trading range roughly $22.00–$23.99. StockAnalysis+1 Below is what’s driving the conversation around Regencell stock right now, based on the latest coverage and filings available on December 23, 2025. RGC stock jumps again on Dec. 23 as it trades
23 December 2025
·····
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,
23 December 2025
····
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back on traders’ radar heading into Dec. 23, 2025, after a sharp move higher to $2.78 at the Dec. 22 close (up 12.10% on the day) and an early pre-market indication around $2.80. StockAnalysis That bounce matters because Iovance has become the kind of stock where small news can hit like a cymbal crash—and not just because it’s biotech. With short interest around one-third of the float (by recent exchange reporting), any new analyst note, operational update, or sentiment shift can amplify price swings. MarketBeat Below is a detailed roundup of the current news,
23 December 2025
···
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus (HSV) programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2 As of the latest available
22 December 2025
·····
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme (Abivax SA) stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index (NBI) becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A (mergers and acquisitions) story. What’s happening with ABIVAX stock today (December 22, 2025) Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be
22 December 2025
··
1 2 3 4 … 6

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop